Abstract ES1-2: Detecting and Managing Immunotherapy-related Toxicities Wisely

Abstract

Abstract With the increasing use of immunotherapy, multidisciplinary breast cancer teams have to get used to recognising and managing immune-related side effects. Although immune checkpoint inhibitors are generally well tolerated, they can cause a wide range of side effects which often differ from those commonly seen with other types of cancer treatment. These immune-mediated side effects include inflammatory or autoimmune reactions which can resemble autoimmune diseases. Side effect patterns can be highly variable in terms of timing, severity and organ manifestation. They appear at any time, sometimes even months after the last treatment, and can affect any part of the body. The risk of developing immune-related side effects generally increases with longer treatment-duration. Most commonly affected body systems are skin, endocrine organs, the gastrointestinal tract, liver and lungs, but even very rare manifestations such as neurological disorders or myocarditis need to be considered as they can be serious. Before considering patients for immunotherapy, they should be carefully assessed with regards the risk of developing immune-related side effects. Patients with a history of autoimmune disorders are generally at risk of worsening of their autoimmune disease with immunotherapy. Early recognition and intervention are critical for the effective management which often includes the use of corticosteroids and occasionally additional immunosuppressive agents. Interdisciplinary working within oncology groups as well as with associated specialties is critical for optimal patients management. With effective management most immune-related side effects resolve and patients can continue their treatment. Citation Format: P Schmid. Detecting and Managing Immunotherapy-related Toxicities Wisely [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr ES1-2.